Emmie de Wit joins TWiV to explain her work on the pathogenesis of infection with SARS-CoV-2 in rhesus macaques, including studies on remdesivir and vaccine candidate.
Daniel Griffin provides a clinical update on COVID-19, then we review an Ad5 vectored SARS-CoV-2 vaccine, reports on remdesivir and hydroxychloroquine, a drug repurposing study, why some patients infect many others, reducing viral transmission, and much more, including listener email.
Jon Yewdell returns to explain studies on detection of antibodies and T cell epitopes in patients who have recovered from COVID-19.
Raul Rabadan joins TWiV to explain the use of computational biology to demonstrate how recombination and mutation led to emergence of SARS-CoV-2.
From the Nipah Virus International Conference in Singapore, Vincent speaks with meeting participants about the history of the first Nipah virus outbreak, lessons learned from Hendra virus, surveillance of bats for viruses, and the development of a vaccine.
Daniel Griffin provides a clinical update on COVID-19, then we review TETRIS by Paterson NJ, modeling the effects of intervention in the US on cases and deaths, mixing PCR and serology data, and much more, including listener email.
Vincent, Kathy and Rich discuss COVID-19 research paper overload, Moderna’s mRNA vaccine Phase I results, increase of ACE2 RNA by cigarette smoke, and answer listener questions.
Vincent speaks with Peter Daszak, President of EcoHealth Alliance, a global nonprofit organization dedicated to protecting wildlife and public health from the emergence of disease.
Daniel Griffin provides a clinical update on COVID-19, then we review results showing requirement for the furin site in the SARS-CoV-2 spike for replication, US state vaccine exemptions, concerns with a rapid diagnostic test, and answers to listener questions.
Vincent, Kathy and Rich explain the Jenner Institute’s SARS-CoV-2 vaccine, the NIH decision to stop the Remdesivir study, and answer listener questions.